IN THIS LESSON: CONCLUSIONS AND FUTURE DIRECTIONS

HEALTH PROFESSIONAL VERSION

Published laser studies establish tPBM as a biologically active, non-invasive neuromodulatory therapy with a favorable safety profile. Mechanistic data from animal models and neuroimaging biomarker changes in human trials confirm that transcranial laser light engages neural substrates involved in TBI, stroke, and neurodegeneration. While early-phase trials show promising efficacy in depression and AD, larger, multicenter randomized trials with standardized laser parameters—wavelength, irradiance, pulsing, and anatomical targeting—are needed to define optimal protocols and secure regulatory indications. For treatment-resistant or chronic neurological conditions, multi-watt NIR laser systems currently offer the most compelling evidence for durable clinical benefit.

Layperson VERSION

Published laser studies show that transcranial photobiomodulation is an active, non-invasive brain therapy with a good safety record.

Animal research and human brain scans confirm that the laser light actually reaches and stimulates brain areas involved in traumatic brain injury, stroke, and neurodegenerative diseases.

Early trials show encouraging results for depression and Alzheimer’s, but bigger, multi-site randomized studies using standardized settings—such as exact wavelength, power level, pulse pattern, and treatment location—are still needed to establish the best protocols and gain formal medical approvals.

For people with long-lasting or hard-to-treat neurological conditions, powerful multi-watt near-infrared laser systems currently provide the strongest published evidence for lasting clinical improvement.